Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients

Differences in clinical effectiveness between angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in the primary treatment of hypertension are unknown. The aim of this retrospective cohort study was to assess the prevention of type 2 diabetes and cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasvold, L P, Bodegård, J, Thuresson, M, Stålhammar, J, Hammar, N, Sundström, J, Russell, D, Kjeldsen, S E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191159/
https://www.ncbi.nlm.nih.gov/pubmed/25211055
http://dx.doi.org/10.1038/jhh.2014.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191159/
https://www.ncbi.nlm.nih.gov/pubmed/25211055
http://dx.doi.org/10.1038/jhh.2014.43

Ejemplares similares